跳至主要内容
临床试验/NCT00696137
NCT00696137已完成3 期

Open-label, Long-term Extension Study for Treatment of Breakthrough Cancer Pain With BEMA™ Fentanyl

BioDelivery Sciences International0 个研究点目标入组 5 人开始时间: 2008年6月最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
5
主要终点
Efficacy Was Not Measured in This Study. The Number of Deaths in the Long Term Follow-up Will be Reported.

研究概览

简要总结

This study is designed to provide continued access to BEMA Fentanyl for those subjects who previously participated in FEN-202 and who wish to continue using BEMA Fentanyl for the treatment of their breakthrough cancer pain.

详细描述

This was an open label, long-term, extension study designed to provide continued access to EMA Fentanyl to those patients with breakthrough cancer pain who were treated for at least 2 weeks in FEN-202, the long term safety study used for worldwide registration. Patients were followed in an outpatient setting. Use of BEMA Fentanyl and occurrence of serious adverse events (SAEs) were monitored. Throughout the study, all patients continued their background opioid regimen and were permitted to use their rescue medication if adequate pain relief was not realized within 30 minutes following application of BEMA Fentanyl.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • previously qualified for and participated in study FEN-202 for at least 2 weeks,
  • wish to continue using BEMA Fentanyl for treatment of breakthrough pain episodes, and
  • provide signed informed consent at screening prior to any study procedures.

排除标准

  • they have developed a new medical condition after initial enrollment in FEN-202 which, in the opinion of the investigator, would preclude safe and appropriate use of BEMA Fentanyl or participation in this study, or
  • there is evidence of improper use of the study drug.

研究组 & 干预措施

BEMA Fentanyl

Experimental

BEMA Fentanyl

干预措施: BEMA Fentanyl (Drug)

结局指标

主要结局

Efficacy Was Not Measured in This Study. The Number of Deaths in the Long Term Follow-up Will be Reported.

时间窗: 3 years

Efficacy was not measured in this study as the intention was to evaluate long term safety in this population. The number of deaths in the long term follow-up will be reported.

次要结局

未报告次要终点

研究者

发起方
BioDelivery Sciences International
申办方类型
Industry
责任方
Sponsor

相似试验